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ABSTRACT 
The Stability of Enrofloxacin 
Meagan Dodge, (Dr. Dawn Boothe) University Undergraduate Fellow, 1997-1998, Texas ARM 
University, Department of Veterinary Clinical Pharmacology 
Enrofloxacin is an antimicrobial drug approved for veterinary use only. Enrofloxacin is 
administered orally or parenterally, Veterinarians may dilute the drug for injection or topical use 
in a commercial physiological solution. The injectable commercially used Enrofloxacin, Baytril, 
is sometimes too strong, causing vomiting, and much smaller concentrations are effective 
topically. It is hypothesized that the dilution of enrofloxacin in some commercially used 
solutions will not affect the drug's efficacy. The purpose of my study was to test the afore stated 
hypothesis. In the experiment, stock solutions of enrofloxacin in physiological saline solution, 
dextrose 5 10 in water, lactated Ringer's solution, Epi-otic solution, and vinegar. E col/ 2592-2 
(standardized solution in saline) was the microorganism chosen to be tested because it is known 
to be susceptible to enrofloxacin. At time 0, I day and 7 days and temperatures of 25 C and 4 G, 
decreasing tube dilutions (0. 125 to 16 Iig/ml) of each stock solution and a standard enrofloxacin 
solution (control) were made using Mueller-Hinton broth. Each dilution of the enrofloxacin 
solution and an equal amount of bacterial solution were combined and incubated for 24 hours. 
The resulting growth was read using ultraviolet spectrophotometry and the minimum inhibitory 
concentration (MIC) of enrofloxacin in each solution was determined and compared to the 
controL Results showed that the MIC's at time 0 were: control - 8 Irg/ml, saline — 0. 25 Itg/ml, 
dextrose - 4 Iig/ml, ringer - I Itg/ml, epi-otic - 4 Iig/ml, and vinegar - 2 Irg/ml. The results for 
both temperatures at I day followed the same pattern. At 7 days, crystals of enrofloxacin were 
observed in all solutions at both temperatures, hence these solutions were not tested by tube 
dilution. Therefore, it can be concluded that because the commercial solutions caused a 
decrease in MIC, they all appear to increase rather than decrease the efficacy of enrofloxacin. 
The experiment shows that some physiological solutions can alter the efficacy of enrofloxacin 
when the two are combined for clinical use, but this alteration is favorable. 
Back~on+ 
Enrofloxacin (ENRO) is a fluoroquinone quinoline carboxylic acid derivative, As an 
antibiotic, this antimicrobial drug is given orally or parenterally to patients suffering from 
susceptible infections. ' Enrofloxacin inhibits DNA gyrase, a bacterial type II topoisomerase, 
responsible for bacterial replication. ' The drug is rapidly bactericidal. 
ENRO is approved for use by veterinarians only. This antibiotic is highly effective 
against aerobic gram-negative rods and coccobacilli, such as Pseudomona aerugi nosa, 
Aeromonas spp. and Pasreurella spp. Selected gram-positive and acid fast bacteria, including 
Staphylococcus aureus and Mycobacteria sp. , are also susceptible. ' 
ENRO can also be administered parenterally. The pharmaceutical product is prepared as 
a 2. 27 lo solution in n-butyl alcohol, potassium hydroxide, and water, which serve only as 
solvents. However, administered from the bottle, concentrations are often too strong, causing 
the patient to vomit. In addition, much smaller concentrations are effective topically. Thus, 
veterinarians may chose to add a small amount of a commercial physiological solution to dilute 
the drug before injection, or they may add the drug to a solution intended for topical use (as in 
the ears). This experiment will determine whether the addition of various dilutents will alter the 
efficacy of the antimicrobial. In addition, the effects of storing the diluted drug up to I week at 
room temperature and in the refrigerator (25'C and 4'C, respectively) will be studied. 
Q) jectives 
The objectives of this study are to determine the inhibitory effects of selected commercially 
available solutions on the antibacterial activity of ENRO. 
H~th 
Our hypothesis is that the efficacy of the ENRO will not be affected by diluting or storing the 
drug in these various solutions. 
terials and Meth s 
The tube dilution method was used to find the minimum inhibitory concentration (MIC) 
of each solution. MIC is the lowest concentration of drug that yields no bacterial growth. The 
solutions tested were physiological saline solution (PSS) [0. 9'/6 NaC1], dextrose 5'/o in water 
(DSW), lactated ringer solution (LRS) [Na, Cl, Ca", and K' as an isotonic fluid], epi-otic fluid 
[2. 7'to lactic acid and 0. 1'/o salicylic acid], vinegar [acetic acid], used as an ear cleaning solution, 
and water as a control. The concentration of ENRO added to the first three solutions (PSS, 
DSW, and LRS) was based on a 5 mg/kg dose (labeled dose) for a twenty kilogram dog. In such 
a case, 100 mg of ENRO would be administered parenterally. For all dilutions, the 
commercially available drug was used, Baytril . To create stock solutions following these 6 
guidelines, 2. 2 ml of Baytril was added to 2. 8 ml of solution, yielding 5 ml of stock. For the 
epi-otic solution and the vinegar, which are administered topically (in the ear), a 1 to 9 dilution 
is generally recommended. I ml of Baytril was added to g ml of solution, yielding 9 ml of 
stock. These five ENRO spiked stock solutions were then tested immediately (time 0) and day I 
and day 7 following storage at 25'C and 4 C. At each time period and at each temperature, 
duplicate dilutions were made using pure ENRO and each of the stock solutions with ENRO 
added. The dilutions used were 16, 8, 4, 2, I, 0. 5, 0. 25, and 0. 125 micrograms/mL. (Figure I) 
The dilutions were made in Mueller-Hinton broth. These dilutions were selected based on the 
clinical response of susceptible microorganisms. 120 microliters of each dilution were added to 
a microplate containing 96 wells (Figure I). The bacteria chosen was E. coli 2592-2, which is 
known to be susceptible to ENRO at the above concentrations. 120 microliters of a solution of 
this bacteria were added to the wells containing the dilutions of each solution. The plate was 
incubated at 3TC overnight. The next day, the inicroplate was read using ultraviolet 
spectrophotometry. The MIC of each solution was that well which contained the lowest 
concentration of ENRO and no growth of organism following a 24 hour incubation. The MIC's 
of each solution was compared to that of the pure ENRO. 
The microbiological assay method will be used to try to gain more convincing results in 
an easier to decipher manner. A concentration of each solution shown to be appropriate for this 
method will be compared to a stock solution of ENRO on a plate of bacteria, E. coli 2592-2. 
Small metal wells, penicylinders, will be placed on top of a lawn of bacteria. The spiked 
solutions and stock solution are added to the wells. The plate is incubated at 37 degrees 
overnight. The next day, the zones of no growth will be measured. Solutions showing the same 
inhibition diameter as the standard are assumed to have retained complete efficacy of the drug, 
This method will also be repeated at zero, one and seven days. 
Results 
The ENRO in each solution crystallized after 7 days of storage. Thus, MIC tube dilutions 
were not done for day 7, since it is assumed that the crystals were of drug. The drug must be 
soluble (that is in solution) to be effective. No clearly satisfactory results could be determined 
from repetition of this method at time 0 and time 1 day. Figures 2-7 cue graphs of log optical 
density versus log concentration of ENRO for each solution at time zero, including the standard 
ENRO solution. The MIC is represented by the point at the baseline of the graph (that is, no 
bacterial growth). Similar graphs were produced from data after one day of incubation. Table 1 
is a summary of the MIC for each solution at each time and temperature. From these data, it is 
apparent that only PSS and LRS affected the efficacy of the drug because the MIC decreased as 
compared to the standard MIC. Hence, the effect was an increased efficacy. However, the 
points on duplicate graphs do not match perfectly. Also, there are points on many graphs that 
show growth at higher concentrations than the MIC point determined (where there is no growth). 
Ideal graphs would show no growth at the MIC and at all points of greater concentration. 
Therefore, these data are not precise enough to be reported as results to my problem. 
The results from the tube dilution method did not support my hypothesis because PSS 
and LRS showed increased efficacy of ENRO. 
The tube dilution method leaves a large margin for human error because of the many 
dilutions required for every plate. The points on the graphs that show unexpected results may be 
due to this complication. The tube dilution method does not directly compare efficacy of the 
drug as a result of the solutions to a standard, but instead efficacy is inferred from MIC 
comparisons. 
In order to solve the problems that arose from the first method used, the microbiological 
assay will be attempted. This method should greatly simplify the experiment and give a better 
indication of how efficacy is affected by each solution. Bioassay utilizes a direct comparison of 
standard efficacy to ENRO spiked solution efficacy by measurement of zone diameter. The 
decision to change inethods was just introduced recently, so no results have been obtained to 
report. The final presentation of my data should include this test also. 
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Table 1: MIC of standard and solutions (micrograms/milliliter) 
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